NCT07342725 2026-01-15Phase Ib/II Study to Evaluate the Safety and Efficacy of IBI363 in Combination With Chemotherapy as Second-Line Therapy for Unresectable Locally Advanced or Metastatic Pancreatic CancerRuijin HospitalPhase 1/2 Not yet recruiting48 enrolled